These findings reinforce the relevance of NRF2 loss to human IPMN pathophysiology and suggest that NRF2 modulates distinct molecular pathways that drive lineage-specific pancreatic tumorigenesis independently of GNAS activation. Here, NFE2L2 is linked to pancreatic intraductal papillary-mucinous neoplasm.